BiotechTube
Respiratorius

Respiratorius

Lund, Sweden· Est.
respiratorius.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

Respiratorius is a clinical-stage biotech company based in Lund, Sweden, developing VAL001, a drug candidate for diffuse large B-cell lymphoma (DLBCL). The company has reported promising Phase I/IIa data showing improved two-year survival and operates a partnership-centric business model to de-risk development. Led by a board and CEO with strong pharmaceutical and financial expertise, Respiratorius is positioned to advance its lead program through further clinical development and potential out-licensing.

OncologyHematology

Technology Platform

Proprietary application of valproate (an HDAC inhibitor) in combination therapy for aggressive lymphoma.

Opportunities

VAL001 addresses a large unmet need in frontline DLBCL treatment, a multi-billion dollar market.
Positive Phase I/IIa survival data creates a strong foundation for securing a development partnership, which could provide non-dilutive funding and accelerate the path to market.

Risk Factors

High dependency on a single asset (VAL001); significant clinical risk that early promising data may not replicate in larger trials; and substantial financial risk due to pre-revenue status and the high cost of pivotal trials, requiring a partner or dilutive financing.

Competitive Landscape

The DLBCL landscape is highly competitive with standard R-CHOP therapy, emerging targeted agents (e.g., Pola-R-CHP), and advanced cell therapies (CAR-T) for relapsed/refractory disease. VAL001's differentiation is improving frontline R-CHOP efficacy, but it must compete for attention and market share against these evolving standards.

More companies in Small Molecule Drugs →More companies in Sweden →